PPLPHARMA Stock Overview
Operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Piramal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹252.20 |
| 52 Week High | ₹307.90 |
| 52 Week Low | ₹114.35 |
| Beta | 0.10 |
| 1 Month Change | 0.82% |
| 3 Month Change | 13.83% |
| 1 Year Change | 79.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 32.74% |
Recent News & Updates
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Recent updates
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Shareholder Returns
| PPLPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.2% | 0.8% | -4.2% |
| 1Y | 79.5% | 39.7% | 19.1% |
Return vs Industry: PPLPHARMA exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: PPLPHARMA exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| PPLPHARMA volatility | |
|---|---|
| PPLPHARMA Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: PPLPHARMA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: PPLPHARMA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 6,719 | n/a | www.piramalpharma.com |
Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene and protection.
Piramal Pharma Limited Fundamentals Summary
| PPLPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹334.35b |
| Earnings (TTM) | ₹453.30m |
| Revenue (TTM) | ₹87.04b |
737.6x
P/E Ratio3.8x
P/S RatioIs PPLPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPLPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹87.04b |
| Cost of Revenue | ₹34.68b |
| Gross Profit | ₹52.36b |
| Other Expenses | ₹51.90b |
| Earnings | ₹453.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 60.15% |
| Net Profit Margin | 0.52% |
| Debt/Equity Ratio | 58.7% |
How did PPLPHARMA perform over the long term?
See historical performance and comparisonDividends
0.04%
Current Dividend Yield79%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Piramal Pharma Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| Prakash Agarwal | Axis Capital Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |